Article
Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation.
Journal of human genetics - 1 Jan 2006
Ohkubo Yumiko, Ueta Akihito, Ando Naoki, Ito Tetsuya, Yamaguchi Sachiko, Mizuno Kantaro, Sumi Satoshi, Maeda Tohru, Yamazaki Daiju, Kurono Yukihisa, Fujimoto Shinji, Togari Hajime
Abstract excerpt
CYP2C19 is a clinically important enzyme involved in the metabolism of therapeutic drugs such as (S)-mephenytoin, omeprazole, proguanil, and diazepam. Individuals can be characterized as either extensive metabolizers (EM) or poor metabolizers (PM) on the basis of CYP2C19 enzyme activity. The PM phenotype occurs in 2-5% of Caucasian populations, but at higher frequencies (18-23%) in Asians. CYP2C19*2 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
